[A21-100] Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2021
Project no.:
A21-100
Commission:
Commission awarded on 01.08.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Haematology
Indication:
Adult patients with newly diagnosed systemic light chain amyloidosis
Result of dossier assessment:
- Patients for whom bortezomib + cyclophosphamide + dexamethasone is the best individual choice: hint of minor added benefit.
- Patients for whom a therapy other than bortezomib + cyclophosphamide + dexamethasone is the best individual choice: added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.